BR112017006598A2 - anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) - Google Patents
anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)Info
- Publication number
- BR112017006598A2 BR112017006598A2 BR112017006598A BR112017006598A BR112017006598A2 BR 112017006598 A2 BR112017006598 A2 BR 112017006598A2 BR 112017006598 A BR112017006598 A BR 112017006598A BR 112017006598 A BR112017006598 A BR 112017006598A BR 112017006598 A2 BR112017006598 A2 BR 112017006598A2
- Authority
- BR
- Brazil
- Prior art keywords
- dprs
- human derived
- antibody
- antidipeptide
- dpr
- Prior art date
Links
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6025—Nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Abstract
trata-se de anticorpos específicos de repetição dipeptídeo derivados de ser humano (dpr) inovadores, assim como variantes sintéticas e derivados biotecnológicos dos mesmos, de preferência, que têm a capacidade de se ligar a dprs c9orf72, assim como métodos relacionados aos mesmos. são também revelados ensaios, kits e suportes sólidos relacionados a anticorpos específicos para dprs e proteínas de dpr, tais como dprs c9orf72. o anticorpo da presente invenção pode ser usado em composições farmacêuticas e diagnósticas para imunoterapia e diagnóstico direcionado à proteína de dpr.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14187180 | 2014-09-30 | ||
EP15180310 | 2015-08-07 | ||
PCT/EP2015/072516 WO2016050822A2 (en) | 2014-09-30 | 2015-09-30 | Human-derived anti-dipeptide repeats (dprs) antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017006598A2 true BR112017006598A2 (pt) | 2018-04-17 |
Family
ID=54238439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017006598A BR112017006598A2 (pt) | 2014-09-30 | 2015-09-30 | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) |
Country Status (17)
Country | Link |
---|---|
US (2) | US10392447B2 (pt) |
EP (1) | EP3201228A2 (pt) |
JP (3) | JP6637971B2 (pt) |
KR (2) | KR20230104759A (pt) |
CN (1) | CN108064248B (pt) |
AU (2) | AU2015326911B2 (pt) |
BR (1) | BR112017006598A2 (pt) |
CA (1) | CA2960925A1 (pt) |
CO (1) | CO2017002804A2 (pt) |
IL (2) | IL278941B (pt) |
MX (1) | MX2017004213A (pt) |
MY (1) | MY180054A (pt) |
NZ (1) | NZ729808A (pt) |
PH (1) | PH12017500489A1 (pt) |
SG (2) | SG10201902850TA (pt) |
WO (1) | WO2016050822A2 (pt) |
ZA (2) | ZA201701733B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2020127664A (ru) | 2012-10-15 | 2020-09-17 | Ионис Фармасьютикалз, Инк. | Композиции для модуляции экспрессии гена c9orf72 |
EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHODS OF MONITORING C9ORF72 EXPRESSION |
AU2014331652B2 (en) | 2013-10-11 | 2020-05-21 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
CN108064248B (zh) | 2014-09-30 | 2022-03-15 | 生物控股有限公司 | 人源抗二肽重复(dpr)抗体 |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
WO2019210054A1 (en) * | 2018-04-27 | 2019-10-31 | Biogen Ma Inc. | Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody |
CN113227116A (zh) * | 2018-10-01 | 2021-08-06 | 联脑科学公司 | 针对源自c9orf72二肽重复蛋白的肽免疫原构建体 |
WO2020092202A2 (en) | 2018-10-29 | 2020-05-07 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
WO2020107037A1 (en) * | 2018-11-25 | 2020-05-28 | President And Fellows Of Harvard College | Compounds and methods for treating neurodegenerative diseases |
WO2020117772A1 (en) | 2018-12-06 | 2020-06-11 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
CN110470837B (zh) * | 2019-08-30 | 2022-09-16 | 苏州西山生物技术有限公司 | 利用猴srv病毒gp20蛋白检测猴srv病毒的方法及其试剂盒 |
WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
EP0574395B1 (en) | 1990-11-09 | 2002-06-12 | GILLIES, Stephen D. | Cytokine immunoconjugates |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
PT669986E (pt) | 1992-11-13 | 2003-08-29 | Idec Pharma Corp | Sequencia do marcador de seleccao dominante alterada e estrategias de insercao intronica para melhoria de expressao de produto genico e sistemas de vector de expressao que o compreendem |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
RO120148B1 (ro) | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
WO2000030680A1 (en) | 1998-11-23 | 2000-06-02 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
EP1373321A2 (en) | 2001-01-29 | 2004-01-02 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
US20100040606A1 (en) * | 2006-03-06 | 2010-02-18 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
KR20090114388A (ko) | 2007-01-05 | 2009-11-03 | 유니버시티 오브 취리히 | 질환 특이적 결합 분자 및 표적을 제공하는 방법 |
US8709382B2 (en) * | 2007-01-11 | 2014-04-29 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
UA106036C2 (uk) * | 2007-11-26 | 2014-07-25 | Баєр Інтеллекчуел Проперті Гмбх | Анти-мезотелінове антитіло та його застосування |
JP2014509588A (ja) * | 2011-03-01 | 2014-04-21 | アムジエン・インコーポレーテツド | 二特異性結合剤 |
CN103796678B (zh) * | 2011-04-20 | 2018-02-27 | 健玛保 | 针对her2的双特异性抗体 |
LT2710033T (lt) * | 2011-05-17 | 2021-06-10 | The Rockefeller University | Žmogaus imunodeficito virusą neutralizuojantys antikūnai ir jų panaudojimo būdai |
CN104185790B (zh) * | 2011-11-11 | 2016-09-28 | 美艾利尔圣地亚哥公司 | 检测杀细胞的毒素(pvl)的装置和方法 |
HUE046434T2 (hu) * | 2013-01-22 | 2020-03-30 | Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V | Dipeptid-ismétlõdõ fehérjék terápiás célpontként neurodegeneratív betegségekben, hexanukleotid ismétlõdõ expanzióval |
WO2014114303A1 (en) | 2013-01-22 | 2014-07-31 | Deutsches Zentrum Für Neurodegenerative Erkrankungen | Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion |
WO2014116865A1 (en) | 2013-01-24 | 2014-07-31 | Mayo Foundation For Medical Education And Research | Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis |
CA2904960A1 (en) | 2013-03-14 | 2014-10-02 | University Of Florida Research Foundation, Inc. | Di-amino acid repeat-containing proteins associated with als |
CN108064248B (zh) | 2014-09-30 | 2022-03-15 | 生物控股有限公司 | 人源抗二肽重复(dpr)抗体 |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
-
2015
- 2015-09-30 CN CN201580064969.8A patent/CN108064248B/zh active Active
- 2015-09-30 MX MX2017004213A patent/MX2017004213A/es unknown
- 2015-09-30 NZ NZ729808A patent/NZ729808A/en unknown
- 2015-09-30 KR KR1020237021848A patent/KR20230104759A/ko not_active Application Discontinuation
- 2015-09-30 JP JP2017517086A patent/JP6637971B2/ja active Active
- 2015-09-30 US US15/508,343 patent/US10392447B2/en active Active
- 2015-09-30 SG SG10201902850TA patent/SG10201902850TA/en unknown
- 2015-09-30 BR BR112017006598A patent/BR112017006598A2/pt not_active Application Discontinuation
- 2015-09-30 EP EP15771953.5A patent/EP3201228A2/en active Pending
- 2015-09-30 KR KR1020177011599A patent/KR102594327B1/ko active IP Right Grant
- 2015-09-30 AU AU2015326911A patent/AU2015326911B2/en active Active
- 2015-09-30 WO PCT/EP2015/072516 patent/WO2016050822A2/en active Application Filing
- 2015-09-30 SG SG11201701925XA patent/SG11201701925XA/en unknown
- 2015-09-30 MY MYPI2017700811A patent/MY180054A/en unknown
- 2015-09-30 IL IL278941A patent/IL278941B/en unknown
- 2015-09-30 CA CA2960925A patent/CA2960925A1/en active Pending
-
2017
- 2017-03-09 ZA ZA2017/01733A patent/ZA201701733B/en unknown
- 2017-03-09 IL IL251081A patent/IL251081A0/en unknown
- 2017-03-14 PH PH12017500489A patent/PH12017500489A1/en unknown
- 2017-03-24 CO CONC2017/0002804A patent/CO2017002804A2/es unknown
-
2018
- 2018-12-07 ZA ZA2018/08270A patent/ZA201808270B/en unknown
-
2019
- 2019-06-07 US US16/434,654 patent/US10961322B2/en active Active
- 2019-11-26 JP JP2019213035A patent/JP2020031660A/ja not_active Withdrawn
-
2021
- 2021-08-20 JP JP2021134979A patent/JP2021177788A/ja active Pending
- 2021-10-06 AU AU2021245147A patent/AU2021245147A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN108064248A (zh) | 2018-05-22 |
NZ729808A (en) | 2022-02-25 |
KR20230104759A (ko) | 2023-07-10 |
CA2960925A1 (en) | 2016-04-07 |
EP3201228A2 (en) | 2017-08-09 |
IL278941A (en) | 2021-01-31 |
MX2017004213A (es) | 2017-07-19 |
WO2016050822A2 (en) | 2016-04-07 |
JP2020031660A (ja) | 2020-03-05 |
JP2017538665A (ja) | 2017-12-28 |
WO2016050822A3 (en) | 2016-06-02 |
IL251081A0 (en) | 2017-04-30 |
JP2021177788A (ja) | 2021-11-18 |
MY180054A (en) | 2020-11-20 |
IL278941B (en) | 2022-07-01 |
KR102594327B1 (ko) | 2023-10-27 |
US10961322B2 (en) | 2021-03-30 |
AU2021245147A1 (en) | 2021-11-04 |
ZA201808270B (en) | 2022-04-28 |
US20200010567A1 (en) | 2020-01-09 |
US20170247471A1 (en) | 2017-08-31 |
SG10201902850TA (en) | 2019-04-29 |
ZA201701733B (en) | 2021-09-29 |
PH12017500489A1 (en) | 2017-08-07 |
KR20170061702A (ko) | 2017-06-05 |
JP6637971B2 (ja) | 2020-01-29 |
AU2015326911B2 (en) | 2021-07-08 |
CO2017002804A2 (es) | 2017-06-20 |
CN108064248B (zh) | 2022-03-15 |
SG11201701925XA (en) | 2017-04-27 |
US10392447B2 (en) | 2019-08-27 |
AU2015326911A1 (en) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
PH12021550083A1 (en) | Human anti-tau antibodies | |
BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
BR112017017025A2 (pt) | métodos e composições para analizar componentes celulares | |
BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
CU20180024A7 (es) | Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas | |
EA201490825A8 (ru) | Tdp-43-специфически связывающие молекулы | |
GT201200271A (es) | Proteínas que se unen al tnf-a | |
UY38203A (es) | Anticuerpo anti-repeticion de dipeptidos (dpr) de (poli-ga) derivado del ser humano | |
MX365387B (es) | Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos. | |
BR112016017764A2 (pt) | anticorpo antidengue de amplo espectro | |
BR112018072118A2 (pt) | anticorpos de interferona beta e usos dos mesmos | |
BR112016016737A2 (pt) | Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma | |
BR112019010128A2 (pt) | proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas | |
TW201613981A (en) | Compositions and methods for the diagnosis of rheumatoid arthritis | |
EA201790437A1 (ru) | Антигенсвязывающие белки, связывающиеся с cxcr3 | |
BR112015017981A2 (pt) | anticorpo humano específico para metapneumovírus humano, ou fragmento de ligação de antígeno do mesmo, seu uso e composição farmacêutica o compreendendo, bem como ácido nucleico isolado, vetor de expressão recombinante e célula hospedeira | |
GB2541596A (en) | Method and composition for determining specific antibody responses to species of filovirus | |
BR112016030008A2 (pt) | método para a detecção de infecção por pegivirus humano 2 em um indivíduo, para a detecção de ácido nucleico de pegivirus humano 2 e para a detecção de pegivirus humano 2 em uma amostra, e, composição | |
BR112016024742A2 (pt) | método para a seleção de uma proteína, proteínas de ligação ao antígeno, anticorpos, imunoconjugado, formulação farmacêutica, uso do anticorpo, ácido nucleico e polipeptídeo | |
EA201892085A1 (ru) | Новые белки, полученные из альфа-1-микроглобулина, и их применение | |
EA202092790A1 (ru) | Происходящее от человека антитело к дипептидным повторам (dpr) | |
BR112017002663A2 (pt) | sistemas e métodos para quantificação e detecção seletivas de alérgenos | |
AR114843A1 (es) | Anticuerpo anti-repetición de dipéptidos (dpr) de (poli-ga) derivado de ser humano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: NEURIMMUNE HOLDING AG (CH) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |